探究术前强化他汀治疗对于高龄冠心病患者冠脉介入治疗预后效果的影响

Exploration on the Effect of Preoperative Statin Strengthening Therapy on the Outcome of Coronary Intervention in Elderly Patients with Coronary Heart Disease

目的分析术前强化他汀治疗对于高龄冠心病患者冠脉介入治疗预后效果的影响。方法方便选取2016年4月—2018年5月期间因冠心病于该院进行治疗的68例患者作为研究对象,所有患者在入院后均采用冠脉介入治疗,对照组在术后予以20 mg瑞舒伐他汀钙进行维持治疗;观察组在对照组用药基础上于术前采用80 mg瑞舒伐他汀钙进行强化治疗。对比两组各项实验室指标及1年内主要不良心血管时间发生情况的差异。结果观察组术后TC、TG、HDL-C、LDL-C分别为(4.44±0.73)mmol/L、(1.38±0.18)mmol/L、(1.21±0.25)mmol/L、(2.90±0.34)mmol/L,对照组术后TC、TG、HDL-C、LDL-C分别为(4.53±0.86)mmol/L、(1.45±0.22)mmol/L、(1.22±0.23)mmol/L、(3.04±0.35)mmol/L,两组在经瑞舒伐他汀钙应用后各项血脂指标显著改善(P<0.05);观察组治疗后CK-MB(21.43±3.40)U/L、TNⅠ(0.15±0.04)μg/L、CRP(17.05±1.83)mg/L,显著高于对照组CK-MB(15.89±3.03)U/L、TNⅠ(0.10±0.03)μg/L、CRP(13.33±1.34)mg/L(P<0.05);观察组心脏不良事件总发生率为5.88%,对照组为17.65%,两组对比差异有统计学意义(χ~2=6.673,P=0.010)。结论高龄冠心病患者冠脉PCI手术前采用强化他汀治疗可有效降低不良心脏事件发生率,用药安全性较高,值得临床推广应用。

Objective To analyze the effect of preoperative statin therapy on coronary intervention in elderly patients with coronary heart disease.Methods 68 patients with coronary heart disease who were treated in the hospital from April 2016 to May 2018 were convenient selected as the study subjects.All patients were treated with coronary intervention after admission.The control group received 20 mg of rosuvulin after surgery.The statin calcium was used for maintenance therapy;the observation group was intensively treated with 80 mg of rosuvastatin calcium before surgery in the control group.The differences between the two groups of laboratory indicators and the occurrence of major adverse cardiovascular events within 1 year were compared.Results The postoperative TC,TG,HDL-C,LDL-C were(4.44±0.73)mmol/L,(1.38±0.18)mmol/L,(1.21±0.25)mmol/L,(2.90±0.34)mmol/L,postoperative TC,TG,HDL-C,and LDL-C were(4.53±0.86)mmol/L,(1.45±0.22)mmol/L,(1.22±0.23)mmol/L,(3.04±0.35)mmol/L,the serum lipids of the two groups were significantly improved after rosuvastatin calcium application(P<0.05);the CK-MB(21.43±3.40)U/L,TNI(0.15±0.04)μg/L,CRP(17.05±1.83)mg/L,significantly higher than the control group CK-MB(15.89±3.03)U/L,TNI(0.10±0.03)μg/L,CRP(13.33±1.34)mg/L(P<0.05);The total incidence of cardiac adverse events was 5.88%in the observation group and 17.65%in the control group.There was a significant difference between the two groups(χ2=6.673,P=0.010).Conclusion The use of fortified statin therapy before coronary artery PCI in elderly patients with coronary heart disease can effectively reduce the incidence of adverse cardiac events,the safety of medication is high,it is worthy of clinical application.